Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis - Top-Institutions - MDSpire

Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis

  • By

  • Hui Zhu

  • Yangxue Ye

  • Lei Fu

  • Weiyan Zhang

  • Bin Wang

  • Xi Chen

  • Yu Lu

  • February 12, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Centers for Disease Control and Prevention (CDC) - Division of Tuberculosis Elimination
    Centers for Disease Control and Prevention (CDC) - Division of Tuberculosis Elimination

    Atlanta, GA

    Key Differentiators

    • Infectious Diseases
    • Tuberculosis Research
    • Pharmacology

  • #2

    University of California, San Francisco (UCSF) - Center for Tuberculosis Research
    University of California, San Francisco (UCSF) - Center for Tuberculosis Research

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Pharmacology
    • Tuberculosis

  • #3

    London School of Hygiene & Tropical Medicine (LSHTM)
    London School of Hygiene & Tropical Medicine (LSHTM)

    London, N/A

    Key Differentiators

    • Infectious Diseases
    • Global Health
    • Pharmacology

  • #4

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Pharmacology

  • #5

    The Aurum Institute
    The Aurum Institute

    Johannesburg, N/A

    Key Differentiators

    • Infectious Diseases
    • Tuberculosis Research
    • Clinical Trials

Original Source(s)

Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis

  • by Hui Zhu, Yangxue Ye, Lei Fu, Weiyan Zhang, Bin Wang, Xi Chen, Yu Lu

  • February 12, 2026

Related Content

Short Antibiotics Match Outcomes in Pneumonia

Only about one in ten hospitalized patients qualified for shorter therapy in a large US analysis

Analysis of infection characteristics and clinical predictive indicators of different bacterial diabetic foot in Yunnan area

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.